Parkman Healthcare Partners established a new $20 million position in EyePoint Pharmaceuticals by purchasing 1.088 million shares in Q4 2025. EyePoint shares have surged 93% over the past year as the company advances DURAVYU, a sustained-release therapy for retinal diseases, with Phase 3 trial data expected mid-2026. Despite significant losses and development-stage operations, the company has sufficient cash runway into late 2027.

Insulet Corp. (NASDAQ:PODD) shares fell to a 52-week low following the announcement of a voluntary Medical Device Correction for certain Omnipod 5 Pods. The manufacturing defect involves a small tear in internal tubing that delivers insulin, potentially causing under-delivery and serious health complications including diabetic ketoacidosis. The company has received 18 reports of serious adverse events. The affected pods represent approximately 1.5% of annual global production. Despite a Buy rating from analysts with a $356.64 price target, technical indicators show mixed momentum with the stock trading below key moving averages.

The global health and wellness sector is projected to reach $6 trillion in annual consumer spending in 2026, driven by demand for functional products and stricter clean-label regulations. Five companies are capitalizing on this trend: Doseology Sciences launched caffeine-based energy pouches; Amneal Pharmaceuticals introduced a new brand identity and plans an Accessibility Index; Prestige Consumer Healthcare expanded its dry eye care portfolio; Viking Therapeutics advanced its obesity drug portfolio with Phase 3 trials; and Insulet expanded its automated insulin delivery system to the Middle East.

BVI announced the appointment of Jim Hollingshead as President & CEO, succeeding Shervin Korangy. Hollingshead brings over 20 years of medical device experience from leadership roles at Insulet and ResMed. BVI has expanded its ophthalmic portfolio with FDA approvals for premium IOLs and new surgical platforms, positioning itself as a challenger in the eye surgery market.

Tandem Diabetes Care reported a Q2 loss of $0.78 per share, missed earnings estimates, and announced a voluntary medical device correction for t:slim X2 insulin pumps due to potential speaker-related issues affecting insulin delivery.

Insulet reported strong Q2 earnings, beating estimates with $649.1 million in revenue, and raised its full-year sales guidance to $2.57-$2.63 billion, driven by increased adoption of its Omnipod 5 insulin pump technology.

The global diabetes care devices market is projected to grow from $33.58 billion in 2024 to $76.44 billion by 2034, driven by increasing diabetes cases, technological advancements, and rising awareness of diabetes management tools.

Several healthcare and AI-driven companies are demonstrating significant potential in transforming medical technologies, offering innovative therapies and solutions across various medical domains like gene editing, telehealth, and precision medicine.

Goldman Sachs is bullish on Dexcom and Insulet, citing their strong positions in the growing diabetes technology market. The firm is neutral on newly listed Beta Bionics, noting its early adoption phase.

Insulet, a medical device company known for its tubeless insulin pump system, saw its stock price surge over 24% in the past five days after reporting strong Q1 earnings and raising its full-year financial outlook.

The global insulin pump market is projected to reach $25.40 billion by 2033, driven by the increasing prevalence of diabetes and advancements in pump technology. India and China are emerging as key growth markets, with factors like government initiatives and rising awareness fueling demand. Leading players in the market include Medtronic, Tandem Diabetes Care, Insulet Corporation, and Roche Diabetes Care.

The wearable patch market is projected to grow at a CAGR of 7.9% from 2024 to 2031, driven by advancements in wearable technologies and the rising demand for preventive healthcare. The blood glucose patch segment is expected to lead the market, while the sports and fitness end-use is anticipated to provide lucrative opportunities.